SGLT2 Inhibitors Linked to Lower Risk of Kidney Stones in Patients With Type 2 Diabetes: Study Shows
Thailand: Use of sodium-glucose co-transporter-2 inhibitors (SGLT2is) may help reduce the risk ofkidney stoneformation in individuals withtype 2 diabetes (T2D)without increasing the likelihood ofurinary tract infections (UTIs), according to new research published inDiabetology & Metabolic Syndrome. The retrospective cohort study highlights potential renal benefits of SGLT2i beyond glucose control.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!